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Follow- up after very preterm 
birth in Europe
Follow- up programmes aim to detect 
neurodevelopmental and health problems 
and enable early interventions for children 
born very preterm (<32 weeks of gesta-
tional age (GA)). Although the impor-
tance of postdischarge follow- up is widely 
acknowledged, recommendations differ 
regarding eligibility criteria, frequency, 
duration and content, especially for 
follow- up beyond early childhood.1–3 We 
used data from a European cohort of chil-
dren born very preterm to describe the use 
of routine follow- up services until 5 years 
of age.
The data were collected for the Effec-
tive Perinatal Intensive care in Europe 
and Screening to Improve Health in Very 
Preterm Infants studies, which constituted 
and followed up an area- based cohort of 
children born very preterm in 2011/2012 
in 19 regions across 11 European coun-
tries.4 Perinatal data were collected from 
obstetric and neonatal records, and 
parents completed questionnaires at 2 and 
5 years of age. Out of 7900 live births, 
6792 were discharged from neonatal care, 
of whom 6759 were alive at 5 years and 
3635 (53.8%) participated in the study.
Based on a question on the use of 
routine follow- up services for children 
born very preterm in the 5- year parental 
questionnaire, we classified children as 
having never used follow- up, no longer 
using follow- up or still using follow- up 
services. We described associations with 
family sociodemographic characteris-
tics and perinatal risks and estimated 
adjusted risks using multinomial regres-
sion models with robust variance esti-
mators for clustered samples and inverse 
probability weights using baseline char-
acteristics to account for study attrition 
bias.4
Of all children, 90.3% had used 
follow- up services, and 27.3% (10.9 to 
58.4% by country) were still doing so 
at 5 years of age (table 1). Never using 
follow- up services was associated with 
maternal sociodemographic characteris-
tics (younger age, low educational level 
and being born outside Europe) and lower 
perinatal risk. Continued follow- up at 
5 years of age was related to perinatal risk 
factors (low GA, small for GA, broncho-
pulmonary dysplasia and male sex). Chil-
dren with mothers born outside of Europe 
were less likely to continue follow- up. 
Adjustments for social and perinatal char-
acteristics failed to explain differences 
between countries.
This study provides novel data on use 
of routine follow- up services after preterm 
birth based on a population- based design 
and standardised questions on follow- up 
from diverse European regions. Limits 
are reliance on parental recall and study 
attrition.
Children from socially disadvantaged 
families were more likely to never use 
follow- up services, corroborating previous 
Table 1 Family sociodemographic and perinatal factors associated with routine follow- up for 
children born very preterm, at 5 years of age
Does child have routine check- ups for children 







Reference: still in follow- up at 5 years
No, never Not anymore
% % % aRRR 95% CI aRRR 95% CI
Mother’s age at delivery (years)
  ≤24 422 17.3 55.2 27.5 2.0 1.2 to 3.5 1.1 0.8 to 1.6
  25–34 2057 9.2 63.0 27.8 ref ref
  ≥35 1098 6.8 67.2 26.0 0.7 0.5 to 1.2 1.0 0.8 to 1.3
Parity at delivery
  Multiparous 2156 8.3 63.6 28.1 ref ref
  Nulliparous 1390 11.2 62.7 26.1 1.1 0.7 to 1.6 1.0 0.8 to 1.2
Multiple birth
  No (singleton) 2531 10.6 62.0 27.4 ref ref
  Yes (twins or more) 1056 7.5 65.4 27.1 0.5 0.3 to 0.9 1.0 0.7 to 1.2
Mother’s educational level
  Lower (ISCED levels 0–2: lower secondary 
or lower)
589 13.7 58.9 27.4 2.0 1.1 to 3.5 0.9 0.7 to 1.3
  Intermediate (ISCED levels 3–5: upper or post- 
secondary, non- tertiary or short cycle tertiary)
1474 9.7 64.0 26.3 1.4 0.9 to 2.2 0.8 0.7 to 1.1
  Higher (ISCED levels 6–8: bachelor degree or 
higher)
1478 6.3 66.3 27.4 Ref Ref
Country of birth
  Native 2857 8.9 63.5 27.6 Ref Ref
  European born 238 7.7 63.9 28.4 0.9 0.4 to 2.0 0.8 0.5 to 1.2
  Born outside Europe 476 13.3 61.9 24.9 2.5 1.4 to 4.2 1.4 1.0 to 1.9
GA, completed weeks
  <26 305 5.5 53.9 40.6 0.2 0.1 to 0.4 0.3 0.2 to 0.5
  26–27 657 6.0 54.2 39.9 0.2 0.1 to 0.4 0.5 0.4 to 0.6
  28–29 937 6.3 66.1 27.6 0.3 0.2 to 0.5 0.7 0.6 to 0.9
  30–31 1688 13.8 66.2 20.0 Ref Ref
Small for GA**
  <3 centile 766 7.7 62.0 30.2 0.5 0.3 to 0.7 0.7 0.5 to 0.9
  3–9 centile 417 11.0 59.3 29.6 1.0 0.6 to 1.6 0.7 0.5 to 0.9
  >10 centile 2404 10.2 63.8 26.0 Ref Ref
Severe neonatal morbidity††
  No 3141 10.4 63.5 26.1 Ref Ref
  Yes 365 5.0 57.7 37.3 0.5 0.2 to 1.1 0.9 0.7 to 1.3
Bronchopulmonary dysplasia
  No 3034 10.7 64.4 24.9 Ref Ref
  Yes 466 3.8 53.8 42.4 0.4 0.2 to 0.8 0.6 0.5 to 0.9
Congenital anomaly
  No 3292 9.9 62.7 27.4 Ref Ref
  Yes 295 8.5 65.5 26.0 0.6 0.3 to 1.2 0.9 0.6 to 1.2
Child sex
  Male 1914 10.0 59.3 30.7 0.9 0.6 to 1.3 0.7 0.6 to 0.9
  Female 1673 9.4 67.1 23.5 Ref Ref
Country (region) (ref sample mean) (ref sample mean)
  Portugal (Lisbon, Northern Region) 425 4.8 36.8 58.4 0.6 0.3 to 1.2 0.2 0.1 to 0.2
  Belgium (Flanders) 259 12.8 40.5 46.7 3.6 2.0 to 6.3 0.3 0.2 to 0.4
  Netherlands (Central Eastern) 146 6.3 52.2 41.5 1.7 0.7 to 4.1 0.5 0.3 to 0.7
  France (Burgundy, Ile- de- France, Northern 
Region)
770 10.3 58.6 31.2 3.0 1.9 to 4.6 0.6 0.5 to 0.8
  Denmark (Eastern Region) 151 10.8 62.5 26.7 6.3 2.9 to 13.8 0.9 0.6 to 1.4
  Sweden (Greater Stockholm) 141 2.8 70.7 26.6 1.1 0.2 to 6.3 1.0 0.7 to 1.5
  UK (East Midlands, Northern, Yorkshire and 
the Humber)
419 13.6 69.4 17.0 10.9 6.1 to 19.4 1.9 1.4 to 2.7
  Germany (Hesse, Saarland) 266 21.5 65.4 13.0 21.1 11.3 to 39.4 1.9 1.2 to 3.1
  Estonia (entire country) 133 0.0 87.2 12.8 0.0 0.0 to 0.0 2.6 1.6 to 4.2
  Italy (Emilia- Romagna, Lazio, Marche) 691 4.5 83.2 12.3 4.5 2.3 to 8.7 2.5 1.9 to 3.3
  Poland (Wielkopolska) 186 13.4 75.7 10.9 18.9 9.4 to 38.3 2.9 1.8 to 4.8
Inverse probability weights after multiple imputation were used for all analyses.
*Using intrauterine charts modelled for the Effective Perinatal Intensive care in Europe cohort.
†Intraventricular haemorrhage grades III and IV, cystic periventricular leucomalacia, retinopathy of prematurity stages III–V or necrotising enterocolitis needing surgery.
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studies.5 This is concerning, as these chil-
dren are more vulnerable to the adverse 
neurodevelopmental consequences of 
preterm birth, and may benefit most from 
interventions. Variation between Euro-
pean countries in the percentage of chil-
dren continuing follow- up at five persisted 
after accounting for perinatal risk factors, 
such as lower GA and neonatal morbidi-
ties. While differences are expected, given 
the heterogeneity in follow- up policies 
and programmes, the magnitude of these 
cross- country disparities, in tandem with 
marked social inequalities at follow- up 
entry, underscore the need for better 
evidence on optimal follow- up organisa-
tion and duration.
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